The many faces of VIP in neuroimmunology: A cytokine rather a neuropeptide?

FASEB Journal

Volumn 18, Issue 12, 2004, Pages 1325-1334

  Pozo, David ^a   Delgado, Mario ^b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Autoimmunity; Immune response; Th cells; Vasoactive intestinal peptide

Indexed keywords

ANTIINFLAMMATORY AGENT; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROTRANSMITTER; NITRIC OXIDE; RANTES; T LYMPHOCYTE RECEPTOR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; BRAIN INJURY; CROHN DISEASE; DENDRITIC CELL; ENDOTOXEMIA; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; LEUKOCYTE MIGRATION; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; NEUROENDOCRINE SYSTEM; NEUROIMMUNOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEPTIC SHOCK; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ALLERGY AND IMMUNOLOGY; ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NEUROLOGY; NEUROPEPTIDES; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; TH2 CELLS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 4344693080     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.03-1440hyp     Document Type: Article

References (45)

1. de Wied, D. (1974) Pituitary peptides and behaviour: influence on motivational, learning and memory processes. Excerpta Med. Int. Congr. Ser. 359, 653-658
2. Kastin, A. J. (2000) What is a neuropeptide? Trends Neurosci. 23, 113-114
3. Strand, F. L. (1999) Neuropeptides: Regulators of Physiological Processes, MIT Press, Cambridge, MA
4. Iversen, L. (1999) Neuopeptides: regulators of physiological processes. Trends Neurosci. 22, 482
5. Piper, P. J., Said, S. I., and Vane, J. R. (1970) Effects on smooth muscle preparations of unidentified vasoactive peptides from intestine and lung. Nature (London) 225, 1144-1146
6. Said, S., and Mutt, V. (1970) Polypeptide with broad biological activity: isolation from small intestine. Science 169, 1217-1218
7. Henning, R. J., and Sawmiller, D. R. (2001) Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc. Res. 49, 27-37
8. Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K., Funk, G.-C., Hamilton, G., Novotny, C., Burian, B., et al. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111, 1339-1346
9. Colwell, C. S., Michel, S., Itri, J., Rodriguez, W., Tam, J., Lelievre, V., Hu, Z., Liu, X., and Waschek, J. A. (2003) Disrupted circadian rhythms in VIP and PHI deficient mice. Am. J. Physiol. 285, R939-R949
10. Ganea, D., and Delgado, M. (2002) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit. Rev. Oral. Biol. Med. 13, 229-237
11. Delgado, M. (2003) VIP: a very important peptide in T helper differentiation. Trends Immunol. 24, 221-224
12. Pozo, D. (2003) VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. Trends Mol. Med. 9, 211-217
13. Delgado, M., Abad, C., Martinez, C., Leceta, J., and Gomariz, R. P. (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7, 563-568
14. Grimm, M. C., Newman, R., Hassim, Z., Cuan, N., Connor, S. J., Le, Y., Wang, J. M., Oppenheim, J. J., and Lloyd, A. R. (2003) Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J. Immunol. 171, 4990-4994
15. Delgado, M., and Ganea, D. (2001) Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166, 2907-2912
16. Delgado, M., Leceta, J., and Ganea, D. (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by upregulating B7.2 expression. J. Immunol. 163, 3629-3635
17. Delgado, M., Reduta, A., Sharma, V., and Ganea, D. (2004) VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4+ T cells. J. Leukoc. Biol. 75, 1122-1130
18. Voice, J. K., Dorsam, G., Lee, H., Kong, Y., and Goetzl, E. J. (2001) Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J. 15, 2489-2496
19. Goetzl, E. J., Voice, J. K., Shen, S., Dorsam, G., Kong, Y., West, K. M., Morrison, C. F., and Harmar, A. J. (2001) Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide. Proc. Natl. Acad. Sci. USA 98, 13854-13859
20. Guerrero, J., Prieto, J., Elorza, F., Ramirez, R., and Goberna, R. (1981) Interaction of vasoactive intestinal peptide with human blood mononuclear cells. Mol. Cell. Endocrinol. 21, 151-160
21. Voice, J. K., Grinninger, C., Kong, Y., Bangale, Y., Paul, S., and Goetzl, E. J. (2003) Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol. 170, 308-314
22. Gozes, I., and Furman, S. (2003) VIP and drug design. Curr. Pharm. Des. 9, 483-494
23. Netea, M. G., van der Meer, J. W., van Deuren, M., and Kullberg, B. J. (2003) Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol. 24, 254-258
24. Delgado, M., Pozo, D., Martinez, C., Leceta, J., Calvo, J., Ganea, D., and Gomariz, R. (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: in vitro and in vivo studies. J. Immunol. 162, 2358-2367
25. Gomariz, R., Leceta, J., Martinez, C., Abad, C., Ganea, D., and Delgado, M. (2000) Anti-inflammatory actions of VIP/PACAP. Role in endotoxemia. N. Y. Acad. Sci. 921, 284-288
26. Delgado, M., and Ganea, D. (2001) Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: in vitro and in vivo. J. Immunol. 167, 966-975
27. Tuncel, N., Tore, F., Sahinturk, V., Ak, D., and Tuncel, M. (2000) Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides 21, 81-89
28. Williams, R. O. (2002) Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum. 46, 271-273
29. Feldmann, M., Brennan, F. M., and Maini, R. N. (1996) Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397-440
30. Delgado, M., Abad, C., Martinez, C., Juarranz, G., Arranz, A., Gomariz, P., and Leceta, J. (2002) Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 80, 16-24
31. Strober, W., Fuss, I. J., and Blumberg, R. S. (2002) The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20, 495-549
32. Abad, C., Martinez, C., Juarranz, M. G., Arranz, A., Leceta, J., Delgado, M., and Gomariz, R. P. (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124, 961-971
33. Nguyen, M. D., Julien, J. P., and Rivest, S. (2002) Innate immunity: the missing link in neuroprotection and neurodegeneration? Nat. Rev. Neurosci. 3, 216-227
34. Delgado, M., and Ganea, D. (2003) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 17, 944-946
35. Bramlett, H. M., and Dietrich, W. D. (2004) Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J. Cereb. Blood Flow Metab. 24, 133-150
36. Yoles, E., Hauben, E., Palgi, O., Agranov, E., Gothilf, A., Cohen, A., Kuchroo, V., Cohen, I. R., Weiner, H., and Schwartz, M. (2001) Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 21, 3740-3748
37. Delgado, M., and Ganea, D. (2003) Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 17, 1922-1924
38. Gozes, I., Divinsky, I., Pilzer, I., Fridkin, M., Brenneman, D. E., and Spier, A. D. (2003) From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J. Mol. Neurosci. 20, 315-322
39. Laburthe, M., Couvineau, A., and Marie, J. C. (2002) VPAC receptors for VIP and PACAP. Receptors Channels 8, 137-153
40. Yung, S. L., Dela Cruz, F., Hamren, S., Zhu, J., Tsutsumi, M., Bloom, J. W., Caudle, M., Roczniak, S., Todd, T., Lemoine, L., et al. (2003) Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide. J. Biol. Chem. 278, 10273-10281
41. Bangale, Y., Karle, S., Planque, S., Zhou, Y. X., Taguchi, H., Nishiyama, Y., Li, L., Kalaga, R., and Paul, S. (2003) VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J. 17, 628-635
42. Pozo, D., Delgado, M., Martinez, C., Gomariz, R., Guerrero, J., and Calvo, J. (1997) Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. Biochim. Biophys. Acta 1359, 250-262
43. 1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochim. Biophys. Acta 135, 249-255
44. Christopoulos, A., Christopoulos, G., Morfis, M., Udawela, M., Laburthe, M., Couvineau, A., Kuwasako, K., Tilakaratne, N., and Sexton, P. M. (2003) Novel receptor partners and function of receptor activity-modifying proteins. J. Biol. Chem. 278, 3293-3297
45. McCulloch, D. A., MacKenzie, C. J., Johnson, M. S., Robertson, D. N., Holland, P. J., Ronaldson, E., Lutz, E. M., and Mitchell, R. (2002) Additional signals from VPAC/PAC family receptors. Biochem. Soc. Trans. 30, 441-446